Clinical Trials Logo

Autophagy clinical trials

View clinical trials related to Autophagy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05279638 Recruiting - Psoriasis Vulgaris Clinical Trials

ATG5 as a Serum Marker of Autophagy in Psoriatic Patient

Start date: February 1, 2022
Phase:
Study type: Observational

it will be of interest to know the ATG 5 as a serum marker of autophagy in serum of psoriasis vulgairs patients and explore its relationship with psoriasis severity.

NCT ID: NCT04160455 Recruiting - HIV Infections Clinical Trials

Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.

ATGALIG-HIV
Start date: November 7, 2019
Phase:
Study type: Observational

Little is known about autophagy during HIV infection. Recently, two different teams reported important dysfunctions of autophagy in HIV-infected patients despite sustained suppressive antiretroviral therapy. As altered autophagy is strongly linked to cellular senescence and chronic inflammation, two hallmarks of HIV-infected patients despite long-term suppressive antiretroviral therapy, it is important to improve our knowledge in the area. Our main objective is to determine whether all or part of mononuclear cell subpopulations (CD4+ and CD8+ T lymphocytes, and monocytes) exhibit a defect in autophagy function in a cohort of HIV-infected patients who are virologically-controlled (plasma HIV RNA <50 copies / ml) either spontaneously (i.e. HIV controllers or post-treatment controllers) or after they started antiretroviral therapy at different time points (i.e. at the acute or chronic phases), as compared with a control group (i.e. uninfected healthy blood donors).

NCT ID: NCT03371758 Recruiting - Autophagy Clinical Trials

Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo

Start date: January 2017
Phase: N/A
Study type: Interventional

The exact mechanism of impairment of autophagy in vitiligo has not yet been determined.